http://www.financespotlight.com/biotech-trump/?utm_source=taboola&utm_medium=referral12/18/16
Could Biotech Market Soar with Donald Trump as President in 2016?Unless you’ve been hiding under a rock, you know that a lot rides on this movement. Political elections, cultural and societal shifts, medical benefits and financial windfalls all play a part, which is why we’d like to take the time to discuss one of the best, and most nuanced, market opportunities you’ll come across all year.
During the presidential campaign, Donald Trump expressed his point of view on the current market. “Be careful of a bubble because what you’ve seen in the past might be small potatoes compared to what happens,” he said in his campaign announcement speech in June..
Donald Trump’s election to the presidency rocked global markets, sending stocks in the U.S. and abroad plunging as investors fled to safe havens like gold. Despite the initial pullback, there are ways to play the markets under a President Trump.
New market opportunities for the same old problems
In each state where the issue was on the ballot—Florida, Arkansas, Montana, and North Dakota—voters supported initiatives that would provide or expand patients’ access to cannabinoid products for ailments that include post-traumatic stress disorder, epilepsy, Parkinson’s disease, cancer, and glaucoma.
And last year at a political rally, Trump said, “In terms of marijuana and legalization, I think that should be a state issue, state-by-state,” adding, “I think medical should happen—right? Don’t we agree? I think so.” – [TheStreet.com]
New market opportunities are rising on the horizon and smart U.S. biotech companies could potentially use the momentum to skyrocket their sales. Prescription painkiller sales are set to increase by 15% and hit $8.4 billion by 2017, due in part to the U.S. Food and Drug Administration’s recent decision to ban any generic versions of OxyContin based on the powerful painkiller’s original formulation, which does not include anti-abuse features designed to make the pill less addictive.
Experts are predicting a race across the pharmaceutical industry to create a market where all opioids have abuse-deterrent properties, according to the Wall Street Journal.
Chronic pain is something that nearly 25 million adult Americans suffer from on a daily basis. Add severe pain to that figure, and now you’re talking upwards of 50 million adults. Many of these tens of millions have no place to turn but to addictive opiates, a last—but only—line of resort for those who are looking to return to some semblance of a normal, functional life. Now think of what it would mean for that opiate market to be totally upended by a powerful but safe alternative. It could saves lives and families.
Pain relief is one of the biggest and broadest ongoing medical challenges of our time, and it’s a problem that’s led to unprecedented opiate addiction. But new science now offers a way out through the use of cannabosides that could replace dangerous opiates for pain relief.
more
